<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03111654</url>
  </required_header>
  <id_info>
    <org_study_id>PI2016_843_0005</org_study_id>
    <nct_id>NCT03111654</nct_id>
  </id_info>
  <brief_title>A Pilot Study on the Prevention of the Vascular RISK Related to Atrial Fibrillation After Intracranial Hemorrhage by Closing the Left Auricle</brief_title>
  <acronym>RIVAFAG</acronym>
  <official_title>A Pilot Study on the Prevention of the Vascular RISK Related to Atrial Fibrillation After Intracranial Hemorrhage by Closing the Left Auricle</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial fibrillation (AF) is a frequent heart rhythm disorder, responsible for the formation&#xD;
      of cardiac thrombi, which can embolize in the systemic circulation, responsible for strokes&#xD;
      (Cerebrovascular accidents). AF increases the risk of stroke and stroke-related disability.&#xD;
      Preventing the thromboembolic risk associated with FMD is therefore a public health issue.&#xD;
      The reference treatment is oral anticoagulation but this treatment is contraindicated in&#xD;
      patients with a history of intracranial hemorrhage. The percutaneous closure of the auricle&#xD;
      is a recent technique which makes it possible to exclude this appendix from the left atrium&#xD;
      where the majority of thrombi are formed in the framework of the AF. Comparative studies have&#xD;
      shown the effectiveness of this technique, appearing to be similar to that of&#xD;
      anticoagulation. However, in view of the per-procedural risk, the indication of closure was&#xD;
      retained by the health authorities only in the event of a contraindication to oral&#xD;
      anticoagulants in patients with non-valvular AF with a high thromboembolic risk. Patients&#xD;
      with a history of intracranial hemorrhage are therefore candidates for this technique, but&#xD;
      there are few studies where these patients were included. The risk-benefit must be&#xD;
      demonstrated over the long term, in terms of ischemic, hemorrhagic recurrence and becoming&#xD;
      functional and cognitive.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 14, 2016</start_date>
  <completion_date type="Actual">October 19, 2017</completion_date>
  <primary_completion_date type="Actual">October 19, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the risk of vascular event (ischemic stroke, haemorrhagic stroke, systemic embolism or cardiovascular or indeterminate death) in patients treated at the Amiens University Hospital with a history of AF and intracranial haemorrhage</measure>
    <time_frame>1 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Intracranial Hemorrhages</condition>
  <arm_group>
    <arm_group_label>Patients with pericardial closure of the auricle</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients without closure of the auricle</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Compare the risk of a vascular event</intervention_name>
    <description>Collected in a post-stroke follow-up consultation, patient clinical outcome data, functional and cognitive disability, standardized, using validated scales.&#xD;
Analysis of selected therapeutic options for the prevention of AF ischemic events.</description>
    <arm_group_label>Patients with pericardial closure of the auricle</arm_group_label>
    <arm_group_label>Patients without closure of the auricle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 18 years or older&#xD;
&#xD;
          -  Affiliation to a social security scheme&#xD;
&#xD;
          -  Non-valvular, paroxysmal, persistent or permanent atrial fibrillation&#xD;
&#xD;
          -  CHA2DS2-VASc greater than or equal to 2&#xD;
&#xD;
          -  History of intracranial haemorrhage: Intra-parenchymal hematoma, subacute or chronic&#xD;
             subcutaneous hematoma And&#xD;
&#xD;
          -  Patients having benefited from the percutaneous closure of the auricle at the&#xD;
             University Hospital of Amiens&#xD;
&#xD;
          -  Either patient admitted to the CHU of Amiens in neurology, neurosurgery or geriatrics&#xD;
             for intracranial haemorrhage, who received standard medical treatment for the&#xD;
             comparison group.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  CHADS2VASC2 less than 2&#xD;
&#xD;
          -  Extradural hematoma&#xD;
&#xD;
          -  Arachnoidal haemorrhage by rupture of aneurysm&#xD;
&#xD;
          -  Haemorrhagic transformation of ischemic stroke&#xD;
&#xD;
          -  Other indication of anticoagulation than FA&#xD;
&#xD;
          -  Modified Rankin scale greater than 4 following intracranial hemorrhage.&#xD;
&#xD;
          -  Early death, in the month following the onset of intracranial hemorrhage.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU Amiens Picardie</name>
      <address>
        <city>Amiens</city>
        <state>Picardie</state>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 7, 2017</study_first_submitted>
  <study_first_submitted_qc>April 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2017</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Hemorrhages</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

